SCHEMBL1799003

SCHEMBL1799003

Cc1nc(-c2c[nH]c3ncc(C4CCCCC4)cc23)cs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK9 P45984 3/20 0.40
▸ MAPK8 P45983 2/20 0.40
▸ MAPK10 P53779 2/20 0.40
▸ CDC7 O00311 4/20 0.36
▸ ROCK1 Q13464 2/20 0.36
▸ SGK2 Q9HBY8 2/20 0.36
▸ MAP4K4 O95819 2/20 0.36
▸ INSR P06213 2/20 0.36
▸ CDK1 P06493 2/20 0.36
▸ PRKACA P17612 2/20 0.36
▸ FLT1 P17948 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ ITK Q08881 2/20 0.36
▸ HIPK2 Q9H2X6 2/20 0.36
▸ MKNK2 Q9HBH9 2/20 0.36
▸ IRAK4 Q9NWZ3 2/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ MAPK13 O15264 1/20 0.36
▸ DAPK3 O43293 1/20 0.36
▸ DYRK3 O43781 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1801278 0.87 MAPK8 (0.54) MAPK9MAPK8MAPK10ROCK1IRAK4
SCHEMBL1801276 0.87 MAPK8 (0.54) MAPK9MAPK8MAPK10ROCK1IRAK4
SCHEMBL1801749 0.86 IL2 (0.39) MAPK9MAPK8MAPK10CDC7ROCK1
SCHEMBL1797816 0.84 MEN1 (0.39) MAPK9MAPK8MAPK10CDC7ROCK1
SCHEMBL8172108 0.83 MAPK8 (0.53) MAPK9MAPK8MAPK10CDC7ROCK1
SCHEMBL1797497 0.83 MAPK8 (0.53) MAPK9MAPK8MAPK10CDC7ROCK1
SCHEMBL1797495 0.83 MAPK8 (0.53) MAPK9MAPK8MAPK10CDC7ROCK1
SCHEMBL1799926 0.83 MAPK8 (0.40) MAPK9MAPK8MAPK10CDC7ROCK1
SCHEMBL1796713 0.83 CAMKK2 (0.43) MAPK9MAPK8MAPK10ROCK1SGK2
SCHEMBL8167221 0.83 MAPK9 (0.39) MAPK9MAPK8MAPK10CDC7ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
EP-2125801-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE Eisai R&D Management Co., Ltd. (JP) 2009-12-02 — — EP disclosed
WO-2008095943-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO. LTD. (JP) 2008-08-14 — — WO disclosed
WO-2008095943-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO. LTD. (JP) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE MAPK7, MAPKAPK5, MAPK13 MAPK9 27/4885MAPK8 33/4885MAPK10 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback